Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are the most frequent indications for stem cell allografts [1] . Disease status and donor source are major determinants of outcomes for these transplantations. Large registry-based analyses illustrate that 3-year overall survival and leukemia-free survival are equivalent in recipients of matched related and matched unrelated donors in AML and MDS [2, 3] . However, one third of patients do not have a matched donor and may have either a mismatched unrelated donor transplantat or depend on alternative donor stem cell sources, such as umbilical cord blood or haploidentical family donors for a transplantat. The experience with either of the latter sources of stem cells is still accumulating, and comparative studies of these with matched donors in a disease-specific context are limited.
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Haploidentical donor transplantation is an attractive option as most patients will have such a donor available. However, severe bidirectional alloreactivity leading to nonengraftment or severe graft-versus-host disease (GVHD) were barriers to these types of transplantations [4] . The Perugia protocol with T cell depletion and infusion of megadoses of CD 34 þ stem cells overcame the problems of engraftment and GVHD, but the associated delayed immune reconstitution resulted in infectious morbidity and mortality [5] . Introduction of a T cellereplete reduced-intensity conditioned haploidentical protocol by the Hopkins group, which is based on the use of bone marrow grafts with lower numbers of T lymphocytes followed by the infusion of high doses of post-transplantation cyclophosphamide (Cy) between 60 to 72 hours after the infusion of stem cells to eliminate maximally alloreactive lymphocytes but spare CD 34 þ stem cells and regulatory T lymphocytes that have the enzyme aldehyde dehydrogenase, resulted in reliable engraftment of neutrophils and platelets with very low rates of acute and chronic GVHD. However, relapse rates were relatively high [6] . Comparisons of overall survival and disease-free survival of reduced-intensity conditioning haploidentical bone marrow transplantations with posttransplantation Cy with double umbilical cord blood transplantations were similar, as the low nonrelapse mortality of haploidentical was offset by the higher relapse rate [7] . To circumvent the higher relapse rate, myeloablative approaches [8, 9] and/or substitution of peripheral blood stem cells have been utilized with higher rates of grade II acute GVHD but similar rates of chronic GVHD [9] [10] [11] [12] . These studies have included all subtypes of hematological malignancies and the relative efficacy of haploidentical donor in reducing relapse is confounded by disease variables. Notably, comparative outcomes based on donor source for relapsed refractory Hodgkin's lymphoma demonstrated significantly lower relapse rates with improved progression-free survival for haploidentical donors and equivalence in terms of 2-year overall survival between matched related donors (MRD), unrelated donors, and haploidentical transplantations [13] . In this issue, Di Stasi et al. address the same question in AML/MDS patients by retrospectively analyzing outcomes of nonrandomized but concurrently treated patients who underwent transplantation with 10/10-matched related or unrelated donors and haploidentical donors conditioned uniformly at their center with a fludarabine/melphalan/thiotepaebased regimen, wherein the doses of melphalan and thiotepa could be reduced for older patients and those with comorbidities. Three different GHVD prophylaxis schemes, including post-transplantation Cy, tacrolimus up to day 180, and mycophenolate for 3 months for haploidentical donors, tacrolimus AE mini methotrexate for MRD, and additional 6 mg/kg of rabbit antithymocyte globulin for matched unrelated donors (MUD) were employed [14] .
Transplantation outcomes for the entire cohort and of those in remission at the time of transplantation showed equivalent 3-year overall survival (matched donors, 56% and haploidentical donors, 66%) and progression-free survival (matched donors, 51% and haploidentical donors, 41%).The rates of acute and chronic GVHD at day 100 and 3 years after transplantation were also similar. Patients in complete remission had favorable outcomes with all donor sources; however, for patients not in complete remission, the progression-free survival with haploidentical transplantation appeared to be worse, although significance was not detected.
Accompanying immune reconstitution studies suggested that all donor types achieved normal CD3 þ counts by 6 months after transplantation with a predominance of CD3 þ /CD8 þ cells, which may account for the low nonrelapse mortality in all groups. Within this, the MRD group recovered CD4 þ /CD8 þ cells to higher levels by day 30 when compared with haploidentical transplant recipients, and natural killer cells were also higher in the haploidentical group at 1 year after transplantation. Unfortunately, the ability to derive correlations between immune reconstitution and outcomes would require larger groups of patients to be studies. The small cohort limits the conclusions we can draw from this study, as exemplified by the trend for MRD to experience better progression-free survival, which may not have been detected statistically, the possibility that acute GVHD incidence was increased in the MUD transplantations, which may have been significant in a larger cohort, and the favorable progression-free survival in the haploidentical cohort may be attributed to larger numbers being in remission and at low/intermediate risk at the time of transplantation. Differences, such as bone marrow being the stem cell source in most haploidentical recipients whereas peripheral blood stem cells was the predominant source in MUD/MRD groups, resulted in significantly longer neutrophil and platelet engraftment times but might also have influenced the incidence of GVHD and relapse rates. Patients undergoing haploidentical transplantations were younger and fitter group with a shorter follow up, whereas those in the MRD/MUD group were older with comorbidities. Whether older patients or those with advanced disease would have comparable results with haploidentical transplantation cannot be determined. An adequately powered study of all 3 donor sources undergoing identical conditioning with post-transplantation Cy as sole prophylaxis and using an identical stem cell source in a single disease matched for relapse risk to detect differences in relapse and GVHD would be the next step. However, more data will be needed before physicians have the confidence to randomize patients into such a trial.
Despite these limitations, this is the first set of data comparing haploidentical donors with 10/10 MRD in AML/ MDS, with encouraging preliminary results. The results go some way in refuting the higher relapse rates associated with haploidentical transplantation and support the authors' assertion that haploidentical donors offer similar results to fully matched unrelated donors in patients with AML/MDS. For the AML/MDS patient who is in complete remission or has low/intermediate disease, for whom no MUD is available or the costs are unaffordable, these data would support the use of haploidentical donors rather than a mismatched unrelated donor. Nevertheless, we must wait for more evidence before we equate or relegate MUD below haploidentical donors.
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